NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Technology Appraisal Committee D meeting minutes

**Minutes:** Confirmed

**Date:** Thursday 12 August 2021

**Location:** Via Zoom

## Attendees

Committee members present

1. Professor Gary McVeigh (Chair) Present for all items
2. Dr Megan John (Shadowing Chair) Items 1 to 4.2.2 & 5.2 to 6.2.2
3. Dr Lindsay Smith (Vice Chair) Present for all items
4. Martin Bradley Present for all items
5. Dr Matthew Bradley Present for all items
6. Professor Sofia Dias Present for all items
7. Professor Rachel Elliott Present for all items
8. Dr Robert Hodgson Present for all items
9. Dr Bernard Khoo Present for all items
10. Ivan Koychev Present for all items
11. Dr Soo Fon Lim Present for all items
12. Professor David Meads Present for all items
13. Malcolm Oswald Present for all items
14. Dr Rebecca Payne Present for all items
15. Professor Chris Parker Present for all items
16. Baljit Singh Present for all items
17. Professor John Watkins Present for all items

NICE staff present

Linda Landells, Associate Director Items 1 to 4.2.2

Jasdeep Hayre, Associate Director Items 5 to 6.2.2

Kate Moore, Project Manager Items 1 to 4.2.2 & 6 to 6.2.2

Gavin Kenny, Project Manager Items 5 to 6.2.2

Sally Doss, Health Technology Assessment Adviser Items 1 to 4.2.2

Christian Griffiths, Health Technology Assessment Adviser Items 5 to 5.2.2

Victoria Kelly, Health Technology Assessment Adviser Items 6 to 6.2.2

Elizabeth Bell, Health Technology Assessment Analyst Items 1 to 4.2.2

Victoria Gillis-Elliott, Health Technology Assessment Analyst Items 5 to 5.2.2

Luke Cowie, Health Technology Assessment Analyst Items 6 to 6.2.2

Emily Eaton Turner, Technical Adviser, Commercial Risk Assessment Items 1 to 5.2.2

Maroulla Whiteley, Business Analyst, RIA Items 1 to 6.1.3

Benjamin Pearce, Senior Medical Editor Items 1 to 4.2.2 & 6 to 6.2.2

Hayley Garnett, Senior Medical Editor Items 5 to 5.2.2

Mandy Tonkinson, role Items 1 to 4.1.3

Laura Marsden, role Items 6 to 6.1.3

Lucinda Evans, Coordinator, MIP Items 5 to 5.1.3

Rosalee Mason, Coordinator, MIP Items 1 to 4.1.3 & 6 to 6.1.3

Gemma Smith, Coordinator, COT Present for all items

Ismahan Abdullah, Administrator, TA Items 5 to 6.2.2

Louise Jones, Administrator, TA Items 5 to 5.2.2

Celia Mayers, Administrator, TA Items 1 to 4.2.2

External review group representatives present

Keith Cooper, Southampton Health Technology Assessment Centre (SHTAC)

Items 1 to 4.1.3

Jonathan Shepherd, Southampton Health Technology Assessment Centre (SHTAC)

Items 1 to 4.1.3

Aline Navega-Biz, School of Health and Related Research (ScHARR) Items 5 to 5.1.3

Paul Tappenden, School of Health and Related Research (ScHARR) Items 5 to 5.1.3

Nigel Fleeman, Liverpool Reviews, and Implementation Group (LRIG) Items 6 to 6.1.3

James Mahon, Liverpool Reviews, and Implementation Group (LRIG) Items 6 to 6.1.3

Experts present

Dr Selina Bhattarai, Consultant Histopathologist, clinical expert nominated by Royal College of Pathologist, Items 1 to 4.1.3

Professor Peter Clark, National Clinical lead for Cancer drugs fund, NHS England, Items 1 to 5.2.2

Professor Syed A Hussain, Professor of Medical Oncology, clinical expert nominated by Roche Products Limited, Items 1 to 4.1.3

Allen Knight, Patient expert, nominated by Action Bladder Cancer UK, Items 1 to 4.1.3

Dr Lydia Makaroff, Patient expert nominated by Fight Bladder Cancer, Items 1 to 4.1.3

Dr Alastair Greystoke, Senior Lecturer in Medical Oncology, clinical expert nominated by MSD, Items 5 to 5.1.3

David Chandler, Patient expert nominated by Psoriasis and Psoriatic Arthritis Alliance, Items 6 to 6.1.3

Helen McAteer, Patient expert nominated by Psoriasis Association, 6 to 6.1.3

Dr Jon Packham, Consultant Rheumatologist, Midlands Partnership NHS Foundation Trust, clinical expert nominated by British Society for Rheumatology, 6 to 6.1.3

## Minutes

### Introduction to the meeting

* 1. The chair welcomed members of the committee and other attendees present to the meeting.
  2. The chair noted committee member apologies.

### News and announcements

* 1. None.

### Minutes from the last meeting

* 1. The committee approved the minutes of the committee meeting held on Wednesday 14 July 2021.

### Appraisal of atezolizumab for untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable - CDF Review of TA492 (ID3777)

* 1. Part 1 – Open session
     1. The chair welcomed the invited clinical & patient experts, the National Clinical lead for Cancer drugs fund external review group representatives, members of the public and company representatives from Roche.
     2. The chair asked all committee members, clinical & patient experts, the National Clinical lead for Cancer drugs fund, external review group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Nominated clinical expert Professor Syed Hussain has declared financial interests as he has received Research funding: CR UK, MRC/NIHR, UHB charities, CCC charities, Northwest Cancer Research, Yorkshire Cancer Research, Bayer, Janssen, Boehringer Ingelheim, Pierre Fabre, Eli Lilly and Advisory board/Consultancy fees from: Roche, MSD, AstraZeneca, BMS, Janssen, GSK, Astellas, Pfizer, Bayer, Pierre Fabre, Ipsen, Sotio, Eisai.
* It was agreed that his declaration would not prevent Professor Hussain from providing expert advice to the committee.
* Nominated patient expert Allen Knight has declared indirect financial interests as Action Bladder Cancer UK has received a donation from a consortium in which Pfizer, a comparator company, has an interest. It is also in discussion with Roche on the possibility of a donation. Such donations are typically in the order of £10,000 and for the general use of the charity.
* It was agreed that his declaration would not prevent Allen from providing expert advice to the committee.
* Nominated clinical expert Dr Lydia Makaroff has declared financial interests as she is an employee of Fight Bladder Cancer who have received financial support from F. Hoffman-La Roche AG, Bristol-Myers Squibb, Janssen Pharmaceutica, Merck KgaA, MSD, and Pfizer you are also a volunteer board member of the World Bladder Cancer Patient Coalition. The World Bladder Cancer Patient Coalition has received financial support from F. Hoffman-La Roche AG, AstraZeneca, Bayer AG, Astellas Pharma, Bristol-Myers Squibb, Ipsen, Janssen Pharmaceutica, Merck KgaA, MSD, Pfizer, Photocure and Seattle Genetics.
* It was agreed that her declaration would not prevent Dr Makaroff from providing expert advice to the committee.
* No further conflicts were declared for this Item.
  + 1. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by the lead team Dr Soo Fon Lim, Professor David Meads and Malcolm Oswald.
  1. Part 2 – Closed session (company representatives, clinical and patient experts, external review group representatives and members of the public were asked to leave the meeting)
     1. The committee then agreed on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD). The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD). in line with their decisions.

### Appraisal of pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer (ID1683)

* 1. Part 1 – Open session
     1. The chair welcomed the invited clinical expert, external review group representatives, the National Clinical lead for Cancer drugs fund, members of the public and company representatives from MSD.
     2. The chair asked all committee members, clinical expert, external review group representatives, the National Clinical lead for Cancer drugs fund, and NICE staff present to declare any relevant interests in relation to the item being considered.
* Committee member Professor David Meads declared financial interest as the university of Leeds has received funding from Celgene and Sanofi for research in an un-related area.
* It was agreed that his declaration would not prevent Professor Meads from participating in this section of the meeting.
* Nominated clinical expert Dr Alistair Greystoke declared financial interests as he has previously received consultancy and speaker fees from MSD.
* It was agreed that his declaration would not prevent Dr Greystoke from providing expert advice to the committee.
* No further conflicts were declared for this item.
  + 1. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by the lead team Dr Robert Hodgson, Professor Chris Parker, and Malcolm Oswald.
  1. Part 2– Closed session (company representatives, clinical expert, external review group representatives and members of the public were asked to leave the meeting).
     1. The committee then agreed on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD). The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD). in line with their decisions.

### Appraisal of upadacitinib for treating active psoriatic arthritis after inadequate response to DMARDs (ID2690)

* 1. Part 1 – Open session
     1. The chair welcomed the invited clinical and patient experts, external review group representatives, members of the public and company representatives from AbbVie.
     2. The chair asked all committee members, clinical and patient experts, external review group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Committee member Professor David Meads declared financial interest as the University of Leeds has received funding from Abbvie, Janssen, Celgene and Sanofi for research in an un-related area.
* It was agreed that his declaration would not prevent Professor Meads from participating in this section of the meeting.
* Nominated patient expert Helen McAteer declared indirect financial interests as Psoriasis Association has received funding from Abbvie, Almirral, Amgen, Eli Lilly, Janssen LEO Pharma and UCB. Helen noted that The Psoriasis Association has a policy that no more than 15% of income can come from the pharmaceutical industry.
* It was agreed that her declarations would not prevent Helen from providing expert advice to committee.
* No further conflicts were declared for this item.
  + 1. The Chair led a discussion of the consultation comments presented to the committee.
  1. Part 2– Closed session (company representatives, clinical and patient experts, external review group representatives and members of the public were asked to leave the meeting).
     1. The committee then agreed on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD). The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD). in line with their decisions.

### Date of the next meeting

The next meeting of the Technology Appraisal Committee D will be held on Thursday 16 September 2021 and will start promptly at 9.30am.